Answers are grounded in this paper and cite their sources.
Antiphage discovery increasingly yields restrictive phenotypes before mechanisms are known. This Perspective argues that reduced plaque formation or low efficiency of plating should be classified phenotype-first, not automatically as immunity. I distinguish immune-gated defenses, replication-niche barriers, and assay-limited phenotypes, and propose a decision-tree workflow using native context, matched physiology, infection-stage readouts, triggers, and phage-mediated rescue. Clearer labels should broadly improve annotation, counter-defense interpretation, and phage-host engineering for therapy, biocontrol, and biotechnology in complex microbial settings.
No takes yet. Share an insight, caveat, or question.
Yong Everett Zhang (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: